%PDF-1.6
%
1 0 obj
<> endobj
3 0 obj
<>stream
2022-07-05T11:36:31+03:00
2022-07-05T11:36:20+03:00
2022-07-05T11:36:31+03:00
Acrobat PDFMaker 17 for Word
uuid:c20caec1-e949-41da-a5ea-97e9797297cb
uuid:26ae6351-7132-43d2-98bd-1c9c61567235
3
application/pdf
Part IB Summary of Product Characteristics
reedj
Adobe PDF Library 17.11.238
D:20220612153354
Accenture
endstream
endobj
4 0 obj
<> endobj
2 0 obj
<>/Metadata 3 0 R
/Outlines 4 0 R
/PageLayout/OneColumn/Pages 7 0 R
/StructTreeRoot 8 0 R
/Type/Catalog>>
endobj
9 0 obj
<> endobj
5 0 obj
<< /A 9 0 R
/Next 11 0 R
/Parent 4 0 R
/Title(1. NAME OF THE MEDICINAL PRODUCT)>> endobj
12 0 obj
<> endobj
11 0 obj
<< /A 12 0 R
/Next 13 0 R
/Parent 4 0 R
/Prev 5 0 R
/Title(2. QUALITATIVE AND QUANTITATIVE COMPOSITION)>> endobj
14 0 obj
<> endobj
13 0 obj
<< /A 14 0 R
/Next 15 0 R
/Parent 4 0 R
/Prev 11 0 R
/Title(3. PHARMACEUTICAL FORM)>> endobj
16 0 obj
<> endobj
15 0 obj
<< /A 16 0 R
/Count 9/First 17 0 R
/Last 18 0 R
/Next 19 0 R
/Parent 4 0 R
/Prev 13 0 R
/Title(4. CLINICAL PARTICULARS)>> endobj
20 0 obj
<> endobj
17 0 obj
<< /A 20 0 R
/Next 21 0 R
/Parent 15 0 R
/Title(4.1 Therapeutic indications)>> endobj
22 0 obj
<> endobj
21 0 obj
<< /A 22 0 R
/Next 23 0 R
/Parent 15 0 R
/Prev 17 0 R
/Title(4.2 Posology and method of administration)>> endobj
24 0 obj
<> endobj
23 0 obj
<< /A 24 0 R
/Next 26 0 R
/Parent 15 0 R
/Prev 21 0 R
/Title(4.3 Contraindications)>> endobj
27 0 obj
<> endobj
26 0 obj
<< /A 27 0 R
/Next 28 0 R
/Parent 15 0 R
/Prev 23 0 R
/Title(4.4 Special warnings and precautions for use)>> endobj
29 0 obj
<> endobj
28 0 obj
<< /A 29 0 R
/Next 31 0 R
/Parent 15 0 R
/Prev 26 0 R
/Title(4.5 Interaction with other medicinal products and other forms of interaction)>> endobj
32 0 obj
<> endobj
31 0 obj
<< /A 32 0 R
/Next 33 0 R
/Parent 15 0 R
/Prev 28 0 R
/Title(4.6 Fertility, pregnancy and lactation)>> endobj
34 0 obj
<> endobj
33 0 obj
<< /A 34 0 R
/Next 36 0 R
/Parent 15 0 R
/Prev 31 0 R
/Title(4.7 Effects on ability to drive and use machines)>> endobj
37 0 obj
<> endobj
36 0 obj
<< /A 37 0 R
/Next 18 0 R
/Parent 15 0 R
/Prev 33 0 R
/Title(4.8 Undesirable effects)>> endobj
38 0 obj
<> endobj
18 0 obj
<< /A 38 0 R
/Parent 15 0 R
/Prev 36 0 R
/Title(4.9 Overdose)>> endobj
40 0 obj
<> endobj
19 0 obj
<< /A 40 0 R
/Count 3/First 41 0 R
/Last 42 0 R
/Next 43 0 R
/Parent 4 0 R
/Prev 15 0 R
/Title(5. PHARMACOLOGICAL PROPERTIES)>> endobj
44 0 obj
<> endobj
41 0 obj
<< /A 44 0 R
/Next 45 0 R
/Parent 19 0 R
/Title(5.1 Pharmacodynamic properties)>> endobj
46 0 obj
<> endobj
45 0 obj
<< /A 46 0 R
/Next 42 0 R
/Parent 19 0 R
/Prev 41 0 R
/Title(5.2 Pharmacokinetic properties)>> endobj
48 0 obj
<> endobj
42 0 obj
<< /A 48 0 R
/Parent 19 0 R
/Prev 45 0 R
/Title(5.3 Preclinical safety data)>> endobj
49 0 obj
<> endobj
43 0 obj
<< /A 49 0 R
/Count 7/First 50 0 R
/Last 51 0 R
/Next 52 0 R
/Parent 4 0 R
/Prev 19 0 R
/Title(6. PHARMACEUTICAL PARTICULARS)>> endobj
53 0 obj
<> endobj
50 0 obj
<< /A 53 0 R
/Next 54 0 R
/Parent 43 0 R
/Title(6.1 List of excipients)>> endobj
55 0 obj
<> endobj
54 0 obj
<< /A 55 0 R
/Next 56 0 R
/Parent 43 0 R
/Prev 50 0 R
/Title(6.2 Incompatibilities)>> endobj
57 0 obj
<> endobj
56 0 obj
<< /A 57 0 R
/Count 1/First 59 0 R
/Last 59 0 R
/Next 60 0 R
/Parent 43 0 R
/Prev 54 0 R
/Title(6.3 Shelf life)>> endobj
61 0 obj
<> endobj
59 0 obj
<< /A 61 0 R
/Parent 56 0 R
/Title(In-use shelf life: Additives:)>> endobj
62 0 obj
<> endobj
60 0 obj
<< /A 62 0 R
/Next 63 0 R
/Parent 43 0 R
/Prev 56 0 R
/Title(6.4 Special precautions for storage)>> endobj
64 0 obj
<> endobj
63 0 obj
<< /A 64 0 R
/Next 51 0 R
/Parent 43 0 R
/Prev 60 0 R
/Title(6.5 Nature and contents of container)>> endobj
65 0 obj
<> endobj
51 0 obj
<< /A 65 0 R
/Parent 43 0 R
/Prev 63 0 R
/Title(6.6 Special precautions for disposal and other handling)>> endobj
66 0 obj
<> endobj
52 0 obj
<< /A 66 0 R
/Next 68 0 R
/Parent 4 0 R
/Prev 43 0 R
/Title(7. REGISTRATION HOLDER)>> endobj
69 0 obj
<> endobj
68 0 obj
<< /A 69 0 R
/Next 6 0 R
/Parent 4 0 R
/Prev 52 0 R
/Title(8. REGISTRATION NUMBER)>> endobj
70 0 obj
<> endobj
6 0 obj
<< /A 70 0 R
/Parent 4 0 R
/Prev 68 0 R
/Title(9. MANUFACTURER)>> endobj
78 0 obj
<> endobj
80 0 obj
<>stream
H\͊@}&uoA\Ĥtcb\S' 'ƺ~wk''wnf>ѝeᚶ>Z
Y)^ݹ?4>ӦO9˿M~.?އOnr^&Ӡ/F^MzN/~>~IL76Tur+ӵbj?^,Gʁ9 !2"W
yc!oo Yz<~ɼD.d쑅Yi0{eVd=̞fi0{=B 4B 4B 4
=#=#=2{ءCa
:0@s9`4@s9`VA9S1S9S1S9S1S9S1S9S1S9SAуE=({PAуE=({P`Ѓooooo
U,~_ 3[:6nvM<8c`>zvtUxe y
endstream
endobj
77 0 obj
<> endobj
82 0 obj
<> endobj
84 0 obj
<>stream
H\Qk@>so
&- Q.='춻\3>LmٲpmL_Ws,Oλ8dU_e7w>cbן8
Onk׆cZo9|^kn=52ІX7!)d"kWc_qcVxxH+
H~o39q9\Kdt(Pҡ0K%d Y,A0K%d Y,A0K,-yfwAwy!\yCwᩜUUUUU'ݕݕݕݍ
ݍglp6:glp6:'v?5ƴu:얮;zFV}
0
endstream
endobj
81 0 obj
<> endobj
85 0 obj
<>stream
xZK8e-RT#dj$\:9mw8v'K =b[Hl_Ng{/~:[xRmŧy]\,#eh-LqEREb$n?1~;1f_Vdy9yWk.X$Jy86ʼnȵ
_T~HŒ,X"Ӳ@)=9)F2Rf~4FQ݊773M(4xl;HP/JgmsTP/^]
ͮ4Mɓlx&De"&dOoHEi7@ Lra"F/p3Wr]ouu/ykn;ZL2IpIotVvPhS3S(ףH5_/qJ߭;o\.3{
+EX(N#=|÷V&H^ֆxp tĹ.ԩ,Js;r45ˌFɵ!'p.,zcKE ?@A,!&K\M7}kX|4ƧW'!V]փ!
g(e\r?Hf:X̍a
h6zqd_9<Vُ6 U*cjU%T o5EDug~
~s1Q_ܴY跅k/ۢ(-Uԋ灢.hHܠ%@
a!#Ʊ7et.eTmsC|~eَ\`JJ>)*ĎWZ56ZuE@
>EgT5E/ƙ&/1A9ѱW##UC58TeYO1s?!T:F\`W<`64\9HOͫmQ":{XHj+cl]x]-DJ'XE%Nac#WIzSzK^@y
G˭ͳBM~;J<竬uyуB1K f)G3:db9Ub斜q=ؼk2(_FMiU'$+^V!@a>&]
OٍY
OZ30T*=h*\SGGxBNLS@9{xvyQw}bcz Q_z0>k2$\C.,$.]vlIZz_qj?) X Q?Ak}o/0A@w𡑖Ġ!#pf7ơ̏@,Ivi혢>ƘG